These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17522870)

  • 1. [Cytokines].
    Feuchtenberger M; Kneitz C; Tony HP
    Z Rheumatol; 2007 Jul; 66(4):297-8, 300-3. PubMed ID: 17522870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highlights in Autoimmunity: 2020.
    Toubi E; Vadasz Z
    Isr Med Assoc J; 2020 Nov; 11(22):717-719. PubMed ID: 33249794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
    Szegedi G
    Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis.
    Chen Z; Bozec A; Ramming A; Schett G
    Nat Rev Rheumatol; 2019 Jan; 15(1):9-17. PubMed ID: 30341437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
    Williams RO; Paleolog E; Feldmann M
    Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
    Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
    BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders.
    Chalubinski M; Broncel M
    Med Sci Monit; 2010 Nov; 16(11):RA245-51. PubMed ID: 20980971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine networks--towards new therapies for rheumatoid arthritis.
    McInnes IB; Liew FY
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):31-9. PubMed ID: 16932625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kitasato symposium 2009: new prospects for cytokine inhibition.
    Burmester GR; Lipsky PE; Dörner T;
    Arthritis Res Ther; 2009; 11(6):301. PubMed ID: 20067593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine patterns and pathogenicity in autoimmune diseases.
    Matei I; Matei L
    Rom J Intern Med; 2002; 40(1-4):27-41. PubMed ID: 15526538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-18 and the treatment of rheumatoid arthritis.
    Dinarello CA
    Rheum Dis Clin North Am; 2004 May; 30(2):417-34, ix. PubMed ID: 15172050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system.
    van den Oever IA; Sattar N; Nurmohamed MT
    Ann Rheum Dis; 2014 Jun; 73(6):954-7. PubMed ID: 24431395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-27: a double agent in the IL-6 family.
    Jones GW; Hill DG; Cardus A; Jones SA
    Clin Exp Immunol; 2018 Jul; 193(1):37-46. PubMed ID: 29437229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptors pathways implication in common autoimmune diseases and therapeutic perspectives.
    Alexoudi I; Kapsimali V; Vaiopoulos A; Kanakis M; Vaiopoulos G
    G Ital Dermatol Venereol; 2015 Apr; 150(2):255-60. PubMed ID: 25876147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis.
    Cook AD; Visvanathan K
    Expert Opin Ther Targets; 2004 Oct; 8(5):375-90. PubMed ID: 15469389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined activation of innate and T cell immunity for recognizing immunomodulatory properties of therapeutic agents.
    Rose B; Herder C; Löffler H; Kolb H; Martin S
    J Leukoc Biol; 2004 Apr; 75(4):624-30. PubMed ID: 14704370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines, inflammation, and autoimmune diseases.
    Ward PA
    Hosp Pract (1995); 1995 May; 30(5):35-41. PubMed ID: 7744979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].
    Waldner MJ; Strangfeld A; Aringer M
    Z Rheumatol; 2016 Feb; 75(1):13-21. PubMed ID: 26786169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.